1 Changes in Chemosensory Sensation during COVID-19

#### ORIGINAL CONTRIBUTION

- 5 Smell, taste and chemesthesis disorders in patients with the SARS-CoV-2
- 6 Omicron variant in China
- 8 Ying Chen<sup>1,†</sup>, Yuying Chen<sup>1,†</sup>, Xiang Liu<sup>2</sup>, Chao Yan<sup>3</sup>, Laiquan Zou<sup>1,\*</sup>
- Chemical Senses and Mental Health Lab, Department of Psychology, School of Public Health,
   Southern Medical University, Guangzhou, Guangdong, China
- Department of Otolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou,
   Guangdong, China
- 14 <sup>3</sup> Key Laboratory of Brain Functional Genomics (MOE & STCSM), Shanghai Changning-ECNU
- Mental Health Center, School of Psychology and Cognitive Science, East China Normal University,
- 16 Shanghai, China

2 3

4

7

9

20 21

- 17 \* Correspondence: zoulq@smu.edu.cn; Tel.: +86-20-62789234
- <sup>†</sup> These authors contributed equally to this work.
- Main text word count: 2336 words

#### SUMMARY

- Background: Chemosensory disorders (including smell, taste and chemesthesis) are among the established symptoms of COVID-19 infection; however, new data indicate that the changes in chemosensory sensation caused by COVID-19 may differ among populations and COVID-19 variants. To date, few studies have focused on the influence of the SARS-CoV-2 Omicron variant on qualitative changes and quantitative reductions in chemosensory function in China.
- Methodology: We conducted a cross □ sectional study of patients with COVID-19 caused by the Omicron variant, to investigate the prevalence of chemosensory disorders and chemosensory function before and during infection, using an online questionnaire.
- Results: A total of 1245 patients with COVID-19 completed the survey. The prevalence rates of smell, taste, and chemesthesis disorders were 69.2%, 67.7%, and 31.4%, respectively. Our data indicate that sex, age, smoking, and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may be associated with
- 36 chemosensory disorders during COVID-19.
- Conclusions: Self-rating of chemosensory function revealed that patients experienced a general decline in smell, taste, and chemesthesis function. Further longitudinal research studies are needed to generate additional data based on objective assessment and investigate the factors influencing chemosensory function in COVID-
- 41 19.

42

44

43 Key words: chemosensory, COVID-19, cross-sectional studies, Omicron, prevalence

#### 45 INTRODUCTION

- 46 Coronavirus disease 2019 (COVID-19) was first detected in Wuhan in December
- 47 2019, and rapidly spread throughout more than 80 countries (1,2). Information from the
- 48 World Health Organization shows that the number of confirmed COVID-19 cases was
- 49 756,411,740 by 16 February, 2023 (https://covid19.who.int). There are reports that
- 50 chemosensory disorders are important symptoms of COVID-19 infection (3-5). Studies
- 51 from the United States, Europe, Malaysia, and Singapore demonstrated that 12%-

88% of COVID-19-infected patients have olfactory and taste disorders (4,6-8), while 52 53 studies from China reported that 5%-25% of patients have smell and/or taste disorder (9,10). The Omicron variant of SARS-CoV-2 was first detected in South Africa in 54 November 2021, and became the main epidemic strain in the world by 15 January 55 2022 (11,12). Some studies have found that the Omicron variant causes less smell and 56 taste dysfunction than non-Omicron SARS-CoV-2 (13-15). Further, a meta-analysis 57 found that the prevalence rates of olfactory dysfunction caused by the Omicron 58 59 variant are 8%–17% and 2%–17% the in UK and USA, respectively (15). In China, the prevalence of olfactory dysfunction caused by the Omicron variant is 60 reported as 0–9% (16-20); however, the sample sizes of studies to date have been 61 relatively small and researchers have focused on patient characteristics and clinical 62 63 symptoms, with insufficient discussion of chemosensory changes. Chemosensory sensation (including smell, taste, and chemesthesis) have important 64 roles in sensing potential threats, such as toxins, bacteria, and chemical irritants (21), 65 66 but most relevant studies have focused solely on smell and taste, and ignored chemesthesis, which is defined as detection of burning, cooling, or tingling in the 67 mouth (5,21). Since these three systems are independent sensory systems, with distinct 68 peripheral and central neural mechanisms (22), it is necessary to explore the influence 69 of COVID-19 on these three senses separately. Further, chemosensory disturbances 70 71 can result in qualitative changes or quantitative reductions in smell or taste, associated 72 with different mechanisms. Qualitative changes include parosmia (things smell 73 different from usual), phantosmia (hallucination of olfactory senses), smell 74 fluctuation, parageusia (distorted taste sensations) and phantogeusia (hallucination of 75 gustatory senses). Quantitative reductions include anosmia (complete loss of 76 olfaction), hyposmia (partial loss of olfaction), ageusia (loss of all or specific gustatory senses) and hypogeusia (reduced ability to taste things) (23,24). Previous 77 78 studies have generally explored changes or reductions of smell and taste, but have 79 rarely classified patient conditions according to the qualitative of the disorders. 80 There is a pressing need to conduct a cross-sectional study to assess the effects of 81 82 83 84

Omicron on patient smell, taste, and chemesthesis in China. The primary aim of this study was to investigate the prevalence of chemosensory disorders, as well as qualitative and quantitative changes of the chemosensory senses during Omicron infection. A secondary aim was to identify factors associated with chemosensory disorders, including sex, age, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or specific conditions, as well as COVID-19 related characteristics.

#### MATERIALS AND METHODS

89 **Participants** 

85

86

87 88

90 Participants answered questions in an online survey about their sociodemographic 91 characteristics, COVID-19 infection status, and smell, taste, and chemesthesis 92 between 20 December 2022 and 20 January 2023. A total of 1311 patients (all aged ≥ 93 18 years) recovered from COVID-19 were invited to participate in the survey. 94 Participants who did not answer all of the questions or failed to pass the lie test were 95 excluded. The final sample consisted of 1245 participants: 983 women (79.0%) and 96 262 men (21.0%), with a mean  $\pm$  standard deviation (SD) age of 25.45  $\pm$  6.57 years 97 old. As this was a cross-sectional study, a 0.95 power estimate, an effect size of 0.3, 98 and an  $\alpha$  value of 0.05 were used to calculate the necessary sample size in the G\*Power program (25). The sample size in our study was far larger than the result 99 100 proposed by the G\*Power program. All participants read an informed consent form 101 and agreed to the use of their data for research. This study received ethics approval

from the Ethics Committee of Southern Medical University.

Data collection

103 104

115116

122

133134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

105 A self-administered questionnaire was used to survey patients who had recovered 106 from COVID-19 in China. The questionnaire was adapted from existing online 107 questionnaires developed by the Global Consortium for Chemosensory Research (GCCR) (5). The GCCR core questionnaire has been implemented in 10 languages as 108 of April 18, 2020, and used or adapted in many other research studies (4,26,27). Data 109 110 collected included demographic information, COVID-19-related characteristics, and 111 patient chemosensory situations, before and during infection. To study the sense of 112 smell and taste in further detail, smell situation options included anosmia, hyposmia, 113 parosmia, phantosmia, and smell fluctuation, and taste situation options included ageusia, hypogeusia, parageusia, and phantogeusia (5,24). 114

Statistical analysis

- 117 Associations between categorical variables were tested using the Chi-Square test.
- 118 Self-ratings of smell, taste, and chemesthesis before and during COVID-19 diagnosis
- 119 were evaluated using the Wilcoxon matched pairs signed-rank test. Statistical
- significance was set at p < 0.05 and all reported p values are two-tailed. All statistical
- analyses were performed using IBM SPSS Statistics (SPSS, version 22).

#### 123 RESULTS

- 124 General prevalence
- 125 Of 1245 patients infected with COVID-19, 69.2% (861/1245) reported having smell
- disorder, 67.7% (843/1245) reported having taste disorder, and 31.4% (391/1245)
- 127 reported chemesthesis disorder (Table 1); the prevalence rates of specific types of
- smell and taste disorder are also shown in Table 1. Among patients who experienced
- anosmia or hyposmia (n = 819), only 12.3% (101/819) reported that the anosmia or
- hyposmia was completely caused by nasal congestion. Further, 56.9% (708/1245) of
- patients reported loss of both smell and taste, 12.3% (153/1245) reported loss of smell
- only, and 10.8% (135/1245) reported loss of taste only.

#### Smell disorder

The data presented in Table 2 show that there was a statistically significant difference in smoking status between patients with and without smell disorder (p < 0.05); where smell disorder was significantly more common among patients who were current or former smokers (p < 0.05). No statistically significant differences in other demographic characteristics, including sex, age group, alcohol intake, chronic rhinitis, allergic rhinitis, and comorbidity or special condition, were found between patients with and without smell disorder (all p > 0.05). Significant differences in rehabilitation status, COVID-19-related symptoms (lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea and fatigue), and COVID-19 vaccination status, were also observed between patients with and without smell disorder (all p < 0.05). Chisquare analysis indicated that patients with symptoms including lack of appetite, dry and sore throat, myalgia, stuffy/running nose, dyspnea, and fatigue, were prone to having smell disorder. Further, patients who did not undergo COVID-19 vaccination were more likely to experience smell disorder (p < 0.05). Associations between specific types of smell disorder (anosmia, hyposmia, parosmia, phantosmia, and olfactory fluctuation) and demographic/COVID-19-related characteristics presented in the supplemental material (Table S1–S5).

Chen et al., 2023 4

- Only 4.8% (60/1245) of patients reported parosmia, while 7.9% (98/1245) reported
- phantosmia. Pleasantness rating score on 100-point scale of the distorted smell caused
- by parosmia was  $25.72 \pm 24.81$  (Mean  $\pm$  SD), and that of phantom smells was  $26.74 \pm$
- 25.98 (Mean  $\pm$  SD). Parosmic individuals mostly reported smells of food (e.g., meat,
- rice, or soup) or other daily necessities (e.g., toothpaste, shampoo, or liquid detergent)
- that became roasted, burnt, or spoiled (e.g., "The smell of chicken soup turned to
- burning"). In phantosmic individuals, the most frequently reported phantom smells
- were smoky, burnt, and rotten.
- Patients rated their smell function before and during COVID-19 on a 100-point scale.
- 161 Compared to scores before COVID-19 (88.53 ± 13.24, Mean ± SD), those during
- 162 COVID-19 (52.38  $\pm$  32.83, Mean  $\pm$  SD) were significantly lower (t = 38.386, p <
- 163 0.001) (Figure 1).
- 165 Taste disorder

164

188

- 166 There were no statistically significant differences in demographic characteristics, such
- as sex, age group, and smoking/alcohol intake, between patients with and without
- taste disorder (all p > 0.05, Table 3). Patients with COVID-19-related symptoms, such
- 169 as lack of appetite, dry and sore throat, myalgia, headache, diarrhea,
- 170 cough/expectoration, stuffy/running nose, dyspnea, and fatigue had a significant
- 171 chance of experiencing taste disorder (all p < 0.05). Associations between specific
- 172 types of taste disorder (ageusia, hypogeusia, parageusia, phantogeusia) and
- demographic/COVID-19-related characteristics are detailed in the supplemental
- material (Table S6-S9). Additionally, of patients with total loss or decrease of
- specific taste (n = 597), 36.9% (220/597) reported total loss or decrease in the taste of
- sour, 45.9% (274/597) of sweet, 20.1% (120/597) of bitter, 51.4% (307/597) of salty,
- 177 and 71.9% (429/597) of umami.
- Parageusia was described in 22.7% (282/1245) of patients, while phantogeusia was
- identified in 26.7% (333/1245) of patients. Pleasantness rating score on 100-point
- scale of the distorted gustatory sense caused by parosmia was  $19.80 \pm 21.33$  (Mean  $\pm$
- SD), while that for gustatory hallucination was  $24.97 \pm 34.38$  (Mean  $\pm$  SD). Most
- patients with parageusia described that the flavors of foods, such as orange, meat, or
- 183 candy, became bitter (e.g., "The rice has turned bitter"). Patients with phantogeusia
- most frequently reported a constant bitter flavor, without anything in mouth.
- Similar to smell, patients rated their taste function before and during COVID-19. The
- score during COVID-19 (58.78  $\pm$  29.74, Mean  $\pm$  SD) was significantly lower than that
- before COVID-19 (90.13  $\pm$  11.60, Mean  $\pm$  SD) (t = 37.173, p < 0.001).
- 189 Chemesthesis disorder
- 190 No significant differences in demographic characteristics, including sex, age group,
- smoking and alcohol intake, chronic rhinitis, allergic rhinitis, and any comorbidity or
- special condition, were found between patients with and without chemesthesis
- 193 disorder (all p > 0.05, Table 4). Significant differences in COVID-19-related
- symptoms (lack of appetite, dyspnea, and fatigue) were detected between patients
- with and without chemesthesis disorder (all p < 0.05).
- 196 Patients also rated their chemesthesis function before and during COVID-19. The
- score during COVID-19 (71.82  $\pm$  26.48, Mean  $\pm$  SD) was also significantly lower
- than that before COVID-19 (88.50  $\pm$  15.83, Mean  $\pm$  SD) (t = 24.700, p < 0.001).
- 200 DISCUSSION
- 201 In the current study, we found that the prevalence rates of smell, taste, and

Chen et al., 2023 5

202 chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron 203 variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Previous studies 204 reported prevalence rates of olfactory dysfunction ranging from 3.2% to 98.3% and of taste dysfunction ranging from 5.6% to 62.7% (28,29). Previous research has found that 205 the reported prevalence of smell, taste, and chemesthesis disorder varies according to 206 207 differences in population, assessment method, and virus strain (28). A meta-analysis 208 based on data from 24 studies, including over 8400 participants from 13 countries, 209 found the pooled prevalence rates of patients with smell and taste dysfunction were 41.0% and 38.2%, respectively (29). Another meta-analysis involving 18 studies 210 211 showed that the prevalence of alteration of the sense of smell or taste was 47% (30). 212 Importantly, recent studies have focused primarily on quantitative changes in smell and taste, while qualitative changes of smell and taste were not addressed (29,31-33); 213 214 however, we included five types of smell disorder (anosmia, hyposmia, parosmia, 215 phantosmia and olfactory fluctuation), and four types of taste disorder (ageusia, 216 hypogeusia, parageusia, phantogeusia) in our study. The prevalence of anosmia in our 217 study was 23.3%, that of hyposmia was 42.5%, ageusia was 19.0%, and hypogeusia 218 was 40.1%. Studies have also found that the prevalence of smell and taste disorder 219 decreased during the period of Omicron variant dominance, but remained more than 30%, similar to our findings (28,34). 220 Males are reported to be more prone to loss of smell and taste senses than females (35); 221 222 however, our data demonstrate that females were more prone to complete loss of olfaction, similar to the findings of Lechien et al. (6,8). In terms of taste loss, we did 223 not detect significant differences between the sexes, similar to Al-Rawi et al. (3,36). 224 225 Further, Al-Rawi et al. found more significant smell and taste loss among individuals 226 in their late 30s (3), consistent with our finding that patients aged 30–39 years are more 227 prone to anosmia and ageusia. Previous research showed that smokers are more vulnerable to anosmia and ageusia (35); however, we detected no significant 228

general.
We also found that some COVID-19 related symptoms, such as lack of appetite, dyspnea, and fatigue, were associated with chemosensory disorder rates. Associations of these factors with chemosensory disorders have been reported in previous research (7,8); however, whether they are risk factors for chemosensory disorders requires further study.

differences between smokers and non-smokers in terms of anosmia and ageusia in our

study. Interestingly, we found that smoking had adverse effects on smell disorders in

229

- 237 In the current study, we report the prevalence, quality, and quantity of chemosensory 238 changes in patients infected with the Omicron variant in China. Patients often confuse 239 chemesthesis with smell and taste when self-reporting, thus our survey included an 240 expanded section relating to chemesthesis, with the aim of better distinguishing the 241 influences of COVID-19 infection on smell, taste and chemesthesis. We also made 242 detailed distinctions among the quality and quantity of changes in smell and taste, and 243 found that these changes differed in the COVID-19 infected population, which may 244 provide reference data for the follow-up research on the mechanism underlying 245 COVID-19 influence on smell and taste. Moreover, we expanded the Chinese version 246 of the GCCR core questionnaire, to provide reference data for future domestic 247 research.
- Our study also had several limitations. First, the participants were mostly from the southern areas of China. Second, the collection of the data for our study was based on
- 250 self-report, which may lead to confirmation bias of chemosensory disorders.
- 251 Additional objective assessment of chemosensory disorders is needed in future

- studies. Third, our study was cross-sectional, and longitudinal studies are needed to
- determine the direction of associations among variables in our study.
- In conclusion, the current study found that the prevalence rates of smell, taste, and
- chemesthesis disorder in 1245 patients with COVID-19 during the period of Omicron
- variant dominance were 69.2%, 67.7%, and 31.4%, respectively. Patients experienced
- a general decline in the function of smell, taste, and chemesthesis. Sex, age, smoking,
- and COVID-19-related symptoms, such as lack of appetite, dyspnea, and fatigue, may
- be associated with chemosensory disorders during COVID-19. The present study
- 260 contributes to existing knowledge of chemosensory disorders in COVID-19 by
- providing Chinese data collected during Omicron variant dominance.

#### ACKNOWLEDGEMENTS

We thank all the participants who participated in our study.

#### **AUTHORSHIP CONTRIBUTION**

- 267 Conceptualization, Laiquan Zou; formal analysis, Ying Chen, Yuying Chen, and
- 268 Laiquan Zou; investigation, Ying Chen, Yuying Chen, Xiang Liu, Chao Yan, and
- 269 Laiquan Zou; writing-original draft, Ying Chen, Yuying Chen, and Laiquan Zou;
- 270 writing—review & editing, Xiang Liu, Chao Yan, and Laiquan Zou. All authors have
- read and agreed to the published version of the manuscript.

#### 273 CONFLICT OF INTEREST

The authors declare that they have no competing interests.

#### 276 FUNDING

277 None.

262263

265266

272

275

278279

280 281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

#### REFERENCES

- 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
  - 2. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
  - 3. Al-Rawi NH, Sammouda AR, AlRahin EA, et al. Prevalence of Anosmia or Ageusia in Patients With COVID-19 Among United Arab Emirates Population. Int Dent J. 2022;72(2):249–56.
  - 4. Lee S-H, Yeoh ZX, Sachlin IS, et al. Self-reported symptom study of COVID-19 chemosensory dysfunction in Malaysia. Sci Rep. 2022;12(1):2111.
  - 5. Parma V, Ohla K, Veldhuizen MG, et al. More Than Smell—COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis. Chem Senses. 2020;45(7):609–22.
  - 6. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–61.
  - 7. Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26(7):1037–40.
- 8. Tham AC, Thein T-L, Lee CS, et al. Olfactory taste disorder as a presenting symptom of COVID-19: a large single-center Singapore study. Eur Arch Otorhinolaryngol. 2021;278(6):1853–62.

9. Song J, Deng Y, Wang H, et al. Self-reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China. 2021;

- 10. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683.
- 11. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet. 2022;399(10335):1618–24.
- 12. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell Mol Immunol. 2022;19(2):293–5.
- 13. Chee J, Chern B, Loh WS, Mullol J, Wang DY. Pathophysiology of SARS-CoV-2 Infection of Nasal Respiratory and Olfactory Epithelia and Its Clinical Impact. Curr Allergy Asthma Rep. 2023;23(2):121–31.
  - 14. Rodriguez-Sevilla JJ, Güerri-Fernádez R, Bertran Recasens B. Is There Less Alteration of Smell Sensation in Patients With Omicron SARS-CoV-2 Variant Infection? Front Med. 2022;9:852998.
  - 15. von Bartheld CS, Wang L. Prevalence of Olfactory Dysfunction with the Omicron Variant of SARS-CoV-2: A Systematic Review and Meta-Analysis. Cells. 2023;12(3):430.
  - 16. Li Q, Liu X, Li L, et al. Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China. Front Med. 2022;9:944909.
  - 17. Liang Y, Mao X, Kuang M, et al. Interleukin-6 affects the severity of olfactory disorder: a cross-sectional survey of 148 patients who recovered from Omicron infection using the Sniffin' Sticks test in Tianjin, China. Int J Infect Dis. 2022;123:17–24.
- 18. Yang W, Yang S, Wang L, et al. Clinical characteristics of 310 SARS-CoV-2 Omicron variant patients and comparison with Delta and Beta variant patients in China. Virol Sin. 2022;37(5):704–15.
  - 19. Zhang H, Chen W, Ye X, et al. Clinical characteristics of patients infected with novel coronavirus wild strain, Delta variant strain and Omicron variant strain in Quanzhou: A real world study. Exp Ther Med. 2022;25(1):62.
  - 20. Shen J, Wu L, Wang P, et al. Clinical characteristics and short-term recovery of hyposmia in hospitalized non-severe COVID-19 patients with Omicron variant in Shanghai, China. Front Med. 2022;9:1038938.
  - 21. Green BG. Chemesthesis and the Chemical Senses as Components of a "Chemofensor Complex." Chem Senses. 2012;37(3):201–6.
- 22. Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and Associated Characteristics. Otolaryngol Neck Surg. 2020;163(1):114–20.
- 23. Iannilli E, Leopold DA, Hornung DE, Hummel T. Advances in Understanding Parosmia: An fMRI Study. ORL. 2019;81(4):185–92.
- 24. Epstein JB, Smutzer G, Doty RL. Understanding the impact of taste changes in oncology care. Support Care Cancer. 2016;24(4):1917–31.
- 348 25. Faul F, Erdfelder E, Lang A-G, Buchner A. G\*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.
- 351 26. Cecchetto C, Di Pizio A, Genovese F, et al. Assessing the extent and timing of

chemosensory impairments during COVID-19 pandemic. Sci Rep. 2021;11(1):17504.

- 27. Albayay J, Fontana L, Parma V, Zampini M. Chemosensory Dysfunction in Long-Term COVID-19 Assessed by Self-Reported and Direct Psychophysical Methods. Life. 2022;12(10):1487.
- 28. Song J, Jing Q, Zhu E, et al. Alterations in smell or taste in individuals infected with SARS-CoV-2 during periods of Omicron variant dominance. Int J Infect Dis. 2023;128:278–84.
- 29. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020;95(8):1621–31.
- 30. Borsetto D, Hopkins C, Philips V, et al. Self-reported alteration of sense of smell or taste in patients with COVID-19: a systematic review and meta-analysis on 3563 patients. Rhinology. 2020;58(5):430–6.
- 31. Luers JC, Rokohl AC, Loreck N, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19). Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;71(16):2262–4.
- 32. Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of Taste and Smell Dysfunction in Coronavirus Disease 2019. JAMA Otolaryngol-- Head Neck Surg. 2020;146(8):1–6.
- 33. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates of parosmia and phantosmia among smell disorders. Chem Senses. 2021;46:bjab046.
- 34. Boscolo□Rizzo P, Tirelli G, Meloni P, et al. Coronavirus disease 2019 (COVID□19)–related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome–coronavirus□2 (SARS□CoV□2) Omicron variant. Int Forum Allergy Rhinol. 2022;12(10):1273–81.
- 35. Al-Ani RM, Acharya D. Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar. Indian J Otolaryngol Head Neck Surg. 2022;74(S2):2703–9.
- 36. Moein ST, Hashemian SM, Mansourafshar B, Khorram ☐ Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID ☐ 19. Int Forum Allergy Rhinol. 2020;10(8):944–50.

# CORRESPONDING AUTHOR

387 Laiquan Zou


- 388 Chemical Senses and Mental Health Lab, Department of Psychology, School of
- 389 Public Health, Southern Medical University, Guangzhou, Guangdong, China
- 390 Tel.: +86-20-62789234
- 391 zoulq@smu.edu.cn;

# **FIGURES**

393394395

399

# Figure 1 The results of self-rating of smell, taste, and chemesthesis function



396 397 \*\*\*p < 0.001.

400 TABLES

402

### 401 Table 1 The prevalence of smell, taste, and chemesthesis disorders among

patients with COVID-19

Variable	n	Total prevalence (N = 1245)	Prevalence in people with smell/taste/chemesthesis disorder
Smell disorder*	861	69.2%	\
Anosmia	290	23.3%	33.7%
Hyposmia	529	42.5%	61.4%
Parosmia	60	4.8%	7.0%
Phantosmia	98	7.9%	11.4%
Smell fluctuation	438	35.2%	50.9%
Taste disorder*	843	67.7%	
Ageusia	236	19.0%	28.0%
Hypogeusia	499	40.1%	59.2%
Parageusia	282	22.7%	33.5%
Phantogeusia	333	26.7%	39.5%
Chemesthesis disorder	391	31.4%	
Complete loss	35	2.8%	9.0%
Partial loss	356	28.6%	91.0%

<sup>403 \*</sup>Multiple responses

Table 2 Association between smell disorder and demographic/COVID-19-related characteristics among patients

Variable         Smell disorder (%)         Total (%)         p value           Sex         Male         170 (19.7)         92 (24.0)         262 (21.0)         0.092           Female         691 (80.3)         292 (76.0)         983 (79.0)         0.092           Age, years         18-29         702 (81.5)         327 (85.2)         1029 (82.7)         30-39         116 (13.5)         38 (9.9)         154 (12.4)         0.204           40-49         30 (3.5)         16 (4.2)         46 (3.7)         0.204         250         13 (1.5)         3 (0.8)         16 (1.3)         5moking         0.204         250         13 (1.5)         3 (0.8)         16 (1.3)         5moking         0.204         250         13 (1.5)         3 (0.8)         16 (1.3)         0.012         40-49         30 (3.5)         16 (4.2)         46 (3.7)         0.204         200         2.30         47 (3.8)         0.012         40-49         30 (3.5)         16 (4.2)         46 (3.7)         0.204         2.20         2.30         47 (3.8)         0.012         420 (48.8)         0.02         2.30         47 (3.8)         0.012         42 (1.9)         44 (3.1)         3.0         0.012         42 (4.2)         43 (4.9)         62.5 (50.2)         0.282         <	406 characteristics among		ici and demogra	apme/COVID-12	7-1 Clateu
Sex         Male         170 (19.7)         92 (24.0)         262 (21.0)         0.092           Age, years         18-29         702 (81.5)         327 (85.2)         1029 (82.7)         30-39         116 (13.5)         38 (9.9)         154 (12.4)         0.204         262 (21.0)				Total (%)	
Male Female       170 (19.7)       92 (24.0)       262 (21.0)       0.092         Female Age, years       30.39       792 (76.0)       983 (79.0)       0.092         18-29       702 (81.5)       327 (85.2)       1029 (82.7)       0.204         30-39       116 (13.5)       38 (9.9)       154 (12.4)       0.204         ≥ 50       13 (1.5)       3 (0.8)       16 (1.3)         Smoking         Current       32 (3.7)       5 (1.3)       37 (3.0)       0.012         Former       38 (4.4)       9 (2.3)       47 (3.8)       0.012         Never       791 (91.9)       370 (96.4)       1161 (93.3)       0.012         Alcohol       791 (91.9)       370 (96.4)       1161 (93.3)       0.0282         Chronic rhinitis         Yes       441 (51.2)       184 (47.9)       625 (50.2)       0.282         Chronic rhinitis         Yes       137 (15.9)       48 (12.5)       185 (14.9)       0.118         Allergic rhinitis         Yes       208 (24.2)       91 (23.7)       299 (24.0)       0.861         Any comorbidity or special condition*       7       42 (10.9)       148 (11.9)       0	Variable		• •		— p value
Female       691 (80.3)       292 (76.0)       983 (79.0)       0.092         Age, years       18–29       702 (81.5)       327 (85.2)       1029 (82.7)       30–39       116 (13.5)       38 (9.9)       154 (12.4)       0.204         40–49       30 (3.5)       16 (4.2)       46 (3.7)       0.204         ≥ 50       13 (1.5)       3 (0.8)       16 (1.3)         Smoking       Urrent       32 (3.7)       5 (1.3)       37 (3.0)       0.012         Former       38 (4.4)       9 (2.3)       47 (3.8)       0.012         Never       791 (91.9)       370 (96.4)       1161 (93.3)       0.12         Alcohol       Yes       441 (51.2)       184 (47.9)       625 (50.2)       0.282         Chronic rhinitis       Yes       137 (15.9)       48 (12.5)       185 (14.9)       0.118         No       724 (84.1)       336 (87.5)       1060 (85.1)       0.118         Allergic rhinitis       Yes       208 (24.2)       91 (23.7)       299 (24.0)       0.861         Any comorbidity or special condition*       Yes       106 (12.3)       42 (10.9)       148 (11.9)       0.489         Method of diagnosis       PCR test       134 (15.6)       67 (17.4)       201 (16	Sex				
Female	Male	170 (19.7)	92 (24.0)	262 (21.0)	0.002
18-29 702 (81.5) 327 (85.2) 1029 (82.7) 30-39 116 (13.5) 38 (9.9) 154 (12.4) 0.204 40-49 30 (3.5) 16 (4.2) 46 (3.7) 0.204 40-49 30 (3.5) 16 (4.2) 46 (3.7) 0.204 250 13 (1.5) 3 (0.8) 16 (1.3)	Female	691 (80.3)	292 (76.0)	983 (79.0)	0.092
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Age, years				
40-49 30 (3.5) 16 (4.2) 46 (3.7) 0.204 ≥ 50 13 (1.5) 3 (0.8) 16 (1.3)  Smoking  Current 32 (3.7) 5 (1.3) 37 (3.0) 0.012  Former 38 (4.4) 9 (2.3) 47 (3.8) 0.012  Never 791 (91.9) 370 (96.4) 1161 (93.3)  Alcohol Yes 441 (51.2) 184 (47.9) 625 (50.2) 0.282  No 420 (48.8) 200 (52.1) 620 (49.8) 0.282  Chronic rhinitis  Yes 137 (15.9) 48 (12.5) 185 (14.9) 0.118  Allergic rhinitis  Yes 208 (24.2) 91 (23.7) 299 (24.0) 0.861  Any comorbidity or special condition*  Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489  Mo 755 (87.7) 342 (89.1) 1097 (88.1) 0.489  Method of diagnosis  PCR test 134 (15.6) 67 (17.4) 201 (16.1) Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706  Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1) 27 (50.0)  Partial 578 (67.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) <0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/eyena 158 (18.4) 43 (11.2) 201 (16.1) 0.002	18–29	702 (81.5)	327 (85.2)	1029 (82.7)	
40.49	30–39	116 (13.5)	38 (9.9)	154 (12.4)	0.204
Smoking         Current         32 (3.7)         5 (1.3)         37 (3.0)         0.012           Former         38 (4.4)         9 (2.3)         47 (3.8)         0.012           Never         791 (91.9)         370 (96.4)         1161 (93.3)           Alcohol         41 (51.2)         184 (47.9)         625 (50.2)         0.282           No         420 (48.8)         200 (52.1)         620 (49.8)         0.282           Chronic rhinitis         724 (84.1)         336 (87.5)         185 (14.9)         0.118           Allergic rhinitis         724 (84.1)         336 (87.5)         1060 (85.1)         0.118           Allergic rhinitis         Yes         208 (24.2)         91 (23.7)         299 (24.0)         0.861           Any comorbidity or special condition*         755 (87.7)         342 (10.9)         148 (11.9)         0.489           Method of diagnosis         755 (87.7)         342 (89.1)         1097 (88.1)         0.489           Method of diagnosis         PCR test         134 (15.6)         67 (17.4)         201 (16.1)         0.489           Method of diagnosis         PCR test         134 (15.6)         67 (17.4)         201 (16.1)         0.706           Symptoms         268 (31.1)         117 (30.5)	40–49	30 (3.5)	16 (4.2)	46 (3.7)	0.204
Current         32 (3.7)         5 (1.3)         37 (3.0)         0.012           Former         38 (4.4)         9 (2.3)         47 (3.8)         0.012           Never         79 (91.9)         370 (96.4)         1161 (93.3)           Alcohol         420 (48.8)         200 (52.1)         625 (50.2)         0.282           No         420 (48.8)         200 (52.1)         620 (49.8)         0.282           Chronic rhinitis         724 (84.1)         336 (87.5)         185 (14.9)         0.118           Allergic rhinitis         724 (84.1)         336 (87.5)         1060 (85.1)         0.118           Allergic rhinitis         724 (84.1)         336 (87.5)         1060 (85.1)         0.118           Allergic rhinitis         728         208 (24.2)         91 (23.7)         299 (24.0)         0.861           Allergic rhinitis         728         208 (24.2)         91 (23.7)         299 (24.0)         0.861           Any comorbidity or special condition*         728         293 (76.3)         946 (76.0)         0.861           Yes         106 (12.3)         42 (10.9)         148 (11.9)         0.489           Method of diagnosis         728         728 (87.7)         342 (89.1)         1097 (88.1)         0.48	≥ 50	13 (1.5)	3 (0.8)	16 (1.3)	
Former Never 791 (91.9) 370 (96.4) 1161 (93.3)  Alcohol  Yes 441 (51.2) 184 (47.9) 625 (50.2) 0.282  No 420 (48.8) 200 (52.1) 620 (49.8) 0.282  Chronic rhinitis  Yes 137 (15.9) 48 (12.5) 185 (14.9) 0.118  Allergic rhinitis  Yes 208 (24.1) 91 (23.7) 299 (24.0) 0.861  Any comorbidity or special condition*  Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489  Method of diagnosis  PCR test 134 (15.6) 67 (17.4) 201 (16.1) Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706  Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140  Symptoms 704 (81.8) 281 (73.2) 985 (79.1) 0.0001  Dyspnea 158 (18.4) 43 (11.2) 201 (16.1) 0.002	Smoking				
Never 791 (91.9) 370 (96.4) 1161 (93.3)  Alcohol  Yes 441 (51.2) 184 (47.9) 625 (50.2) 0.282  No 420 (48.8) 200 (52.1) 620 (49.8) 0.282  Chronic rhinitis  Yes 137 (15.9) 48 (12.5) 185 (14.9) 0.118  Allergic rhinitis  Yes 208 (24.2) 91 (23.7) 299 (24.0) 0.861  Any comorbidity or special condition#  Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489  No 755 (87.7) 342 (89.1) 1097 (88.1) 0.489  Method of diagnosis  PCR test 134 (15.6) 67 (17.4) 201 (16.1) 4.19 (16.1) 4.	Current	32 (3.7)	5 (1.3)	37 (3.0)	0.012
Alcohol Yes	Former	38 (4.4)	9 (2.3)	47 (3.8)	0.012
Yes         441 (51.2)         184 (47.9)         625 (50.2)         0.282           No         420 (48.8)         200 (52.1)         620 (49.8)         0.282           Chronic rhinitis         Yes         137 (15.9)         48 (12.5)         185 (14.9)         0.118           No         724 (84.1)         336 (87.5)         1060 (85.1)         0.118           Allergic rhinitis         Yes         208 (24.2)         91 (23.7)         299 (24.0)         0.861           No         653 (75.8)         293 (76.3)         946 (76.0)         0.861           Any comorbidity or special condition*         Yes         106 (12.3)         42 (10.9)         148 (11.9)         0.489           No         755 (87.7)         342 (89.1)         1097 (88.1)         0.489           Method of diagnosis         PCR test         134 (15.6)         67 (17.4)         201 (16.1)         0.489           Method of diagnosis         PCR test         134 (15.6)         67 (17.4)         201 (16.1)         0.706           Symptoms         268 (31.1)         117 (30.5)         385 (30.9)         0.706           Rehabilitation status         Complete         283 (32.9) <td< td=""><td>Never</td><td>791 (91.9)</td><td>370 (96.4)</td><td>1161 (93.3)</td><td></td></td<>	Never	791 (91.9)	370 (96.4)	1161 (93.3)	
No 420 (48.8) 200 (52.1) 620 (49.8) 0.282  Chronic rhinitis Yes 137 (15.9) 48 (12.5) 185 (14.9) No 724 (84.1) 336 (87.5) 1060 (85.1) 0.118  Allergic rhinitis Yes 208 (24.2) 91 (23.7) 299 (24.0) No 653 (75.8) 293 (76.3) 946 (76.0) 0.861  Any comorbidity or special condition* Yes 106 (12.3) 42 (10.9) 148 (11.9) No 755 (87.7) 342 (89.1) 1097 (88.1) 0.489  Method of diagnosis PCR test 134 (15.6) 67 (17.4) 201 (16.1) Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706 Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140  Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001  Dyspnea	Alcohol				
No 420 (48.8) 200 (52.1) 620 (49.8)  Chronic rhinitis  Yes 137 (15.9) 48 (12.5) 185 (14.9)  No 724 (84.1) 336 (87.5) 1060 (85.1)  Allergic rhinitis  Yes 208 (24.2) 91 (23.7) 299 (24.0)  No 653 (75.8) 293 (76.3) 946 (76.0)  Any comorbidity or special condition*  Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489  No 755 (87.7) 342 (89.1) 1097 (88.1)  Method of diagnosis  PCR test 134 (15.6) 67 (17.4) 201 (16.1)  Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706  Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140  Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001  Dyspnea	Yes	441 (51.2)	184 (47.9)	625 (50.2)	0.282
Yes         137 (15.9)         48 (12.5)         185 (14.9)         0.118           No         724 (84.1)         336 (87.5)         1060 (85.1)         0.118           Allergic rhinitis         208 (24.2)         91 (23.7)         299 (24.0)         0.861           No         653 (75.8)         293 (76.3)         946 (76.0)         0.861           Any comorbidity or special condition.         55 (87.7)         329 (10.9)         148 (11.9)         0.489           No         755 (87.7)         342 (89.1)         1097 (88.1)         0.489           Method of diagnosis         8         134 (15.6)         67 (17.4)         201 (16.1)         0.489           Method of diagnosis         9CR test         134 (15.6)         67 (17.4)         201 (16.1)         0.489           Method of diagnosis         9CR (est         134 (15.6)         67 (17.4)         201 (16.1)         0.489           Method of diagnosis         9CR (est         134 (15.6)         67 (17.4)         201 (16.1)         0.706           Symptoms         268 (31.1)         117 (30.5)         385 (30.9)         0.706           Symptoms         283 (32.9)         167 (43.5)         450 (36.1)         0.001           Partial         578 (67.1)	No	420 (48.8)	200 (52.1)	620 (49.8)	0.262
No 724 (84.1) 336 (87.5) 1060 (85.1) 0.118  Allergic rhinitis Yes 208 (24.2) 91 (23.7) 299 (24.0) 0.861  No 653 (75.8) 293 (76.3) 946 (76.0) 0.861  Any comorbidity or special condition# Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489  No 755 (87.7) 342 (89.1) 1097 (88.1) 0.489  Method of diagnosis PCR test 134 (15.6) 67 (17.4) 201 (16.1) 4.00 (16	Chronic rhinitis				
Allergic rhinitis Yes 208 (24.2) 91 (23.7) 299 (24.0) 0.861 No 653 (75.8) 293 (76.3) 946 (76.0) 0.861 Any comorbidity or special condition# Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489 No 755 (87.7) 342 (89.1) 1097 (88.1) 0.489 Method of diagnosis PCR test 134 (15.6) 67 (17.4) 201 (16.1) Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706 Symptoms 268 (31.1) 117 (30.5) 385 (30.9) Rehabilitation status Complete 283 (32.9) 167 (43.5) 450 (36.1) 217 (56.5) 795 (63.9) Symptoms* Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206 Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) <0.001 Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011 Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008 Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328 Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140 Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140 Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001 Dyspnea	Yes	137 (15.9)	48 (12.5)	185 (14.9)	Λ 110
Yes         208 (24.2)         91 (23.7)         299 (24.0)         0.861           No         653 (75.8)         293 (76.3)         946 (76.0)         0.861           Any comorbidity or special condition#         Yes         106 (12.3)         42 (10.9)         148 (11.9)         0.489           No         755 (87.7)         342 (89.1)         1097 (88.1)         0.489           Method of diagnosis         PCR test         134 (15.6)         67 (17.4)         201 (16.1)         42.00           Antigen test         459 (53.3)         200 (52.1)         659 (52.9)         0.706           Symptoms         268 (31.1)         117 (30.5)         385 (30.9)           Rehabilitation status         Complete         283 (32.9)         167 (43.5)         450 (36.1)         40.001           Partial         578 (67.1)         217 (56.5)         795 (63.9)         <0.001	No	724 (84.1)	336 (87.5)	1060 (85.1)	0.116
No       653 (75.8)       293 (76.3)       946 (76.0)       0.861         Any comorbidity or special condition.**	Allergic rhinitis				
Any comorbidity or special condition   Yes	Yes	208 (24.2)	91 (23.7)	299 (24.0)	0.861
Condition# Yes 106 (12.3) 42 (10.9) 148 (11.9) 0.489 No 755 (87.7) 342 (89.1) 1097 (88.1)  Method of diagnosis  PCR test 134 (15.6) 67 (17.4) 201 (16.1) Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706 Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1) Partial 578 (67.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206 Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001 Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011 Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008 Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328 Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140 Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140 Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001 Dyspnea	No	653 (75.8)	293 (76.3)	946 (76.0)	0.801
Yes       106 (12.3)       42 (10.9)       148 (11.9)       0.489         No       755 (87.7)       342 (89.1)       1097 (88.1)       0.489         Method of diagnosis       PCR test       134 (15.6)       67 (17.4)       201 (16.1)       20.00       20.00         Antigen test       459 (53.3)       200 (52.1)       659 (52.9)       0.706         Symptoms       268 (31.1)       117 (30.5)       385 (30.9)         Rehabilitation status       Complete       283 (32.9)       167 (43.5)       450 (36.1)       450 (36.1)         Partial       578 (67.1)       217 (56.5)       795 (63.9)       20.001         Symptoms*       Fever       818 (95.0)       358 (93.2)       1176 (94.5)       0.206         Lack of appetite       547 (63.5)       168 (43.8)       715 (57.4)       <0.001					
No       755 (87.7)       342 (89.1)       1097 (88.1)         Method of diagnosis       PCR test       134 (15.6)       67 (17.4)       201 (16.1)         Antigen test       459 (53.3)       200 (52.1)       659 (52.9)       0.706         Symptoms       268 (31.1)       117 (30.5)       385 (30.9)         Rehabilitation status       Complete       283 (32.9)       167 (43.5)       450 (36.1)					
No       755 (87.7)       342 (89.1)       1097 (88.1)         Method of diagnosis       PCR test       134 (15.6)       67 (17.4)       201 (16.1)         Antigen test       459 (53.3)       200 (52.1)       659 (52.9)       0.706         Symptoms       268 (31.1)       117 (30.5)       385 (30.9)         Rehabilitation status       Complete       283 (32.9)       167 (43.5)       450 (36.1)		, ,		, ,	0.489
PCR test       134 (15.6)       67 (17.4)       201 (16.1)         Antigen test       459 (53.3)       200 (52.1)       659 (52.9)       0.706         Symptoms       268 (31.1)       117 (30.5)       385 (30.9)         Rehabilitation status       Complete       283 (32.9)       167 (43.5)       450 (36.1)		755 (87.7)	342 (89.1)	1097 (88.1)	0.40)
Antigen test 459 (53.3) 200 (52.1) 659 (52.9) 0.706  Symptoms 268 (31.1) 117 (30.5) 385 (30.9)  Rehabilitation status  Complete 283 (32.9) 167 (43.5) 450 (36.1)  Partial 578 (67.1) 217 (56.5) 795 (63.9)  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140  Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001  Dyspnea	E .				
Symptoms       268 (31.1)       117 (30.5)       385 (30.9)         Rehabilitation status       283 (32.9)       167 (43.5)       450 (36.1)         Complete       283 (67.1)       217 (56.5)       795 (63.9)         Partial       578 (67.1)       217 (56.5)       795 (63.9)         Symptoms*       **       **         Fever       818 (95.0)       358 (93.2)       1176 (94.5)       0.206         Lack of appetite       547 (63.5)       168 (43.8)       715 (57.4)       < 0.001		· · ·	, ,	, ,	
Rehabilitation status         Complete       283 (32.9)       167 (43.5)       450 (36.1)       < 0.001	_	` ′		, ,	0.706
Complete Partial       283 (32.9)       167 (43.5)       450 (36.1)       < 0.001	• •	268 (31.1)	117 (30.5)	385 (30.9)	
Partial 578 (67.1) 217 (56.5) 795 (63.9) < 0.001  Symptoms*  Fever 818 (95.0) 358 (93.2) 1176 (94.5) 0.206  Lack of appetite 547 (63.5) 168 (43.8) 715 (57.4) < 0.001  Dry and sore throat 692 (80.4) 284 (74.0) 976 (78.4) 0.011  Myalgia 604 (70.2) 240 (62.5) 844 (67.8) 0.008  Headache 598 (69.5) 256 (66.7) 854 (68.6) 0.328  Diarrhea 191 (22.2) 71 (18.5) 262 (21.0) 0.140  Cough/expectoration 747 (86.8) 321 (83.6) 1068 (85.8) 0.140  Stuffy/running nose 704 (81.8) 281 (73.2) 985 (79.1) 0.001  Dyspnea 158 (18.4) 43 (11.2) 201 (16.1) 0.002					
Symptoms*       \$78 (67.1)       \$217 (56.5)       795 (63.9)         Symptoms*       \$18 (95.0)       \$358 (93.2)       \$1176 (94.5)       \$0.206         Lack of appetite       \$547 (63.5)       \$168 (43.8)       \$715 (57.4)       \$<0.001	•	· · ·	` ,	, ,	< 0.001
Fever       818 (95.0)       358 (93.2)       1176 (94.5)       0.206         Lack of appetite       547 (63.5)       168 (43.8)       715 (57.4)       < 0.001	ماد	578 (67.1)	217 (56.5)	795 (63.9)	< 0.001
Lack of appetite       547 (63.5)       168 (43.8)       715 (57.4)       < 0.001	* =				
Dry and sore throat       692 (80.4)       284 (74.0)       976 (78.4)       0.011         Myalgia       604 (70.2)       240 (62.5)       844 (67.8)       0.008         Headache       598 (69.5)       256 (66.7)       854 (68.6)       0.328         Diarrhea       191 (22.2)       71 (18.5)       262 (21.0)       0.140         Cough/expectoration       747 (86.8)       321 (83.6)       1068 (85.8)       0.140         Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002		, ,	, ,	, ,	
Myalgia       604 (70.2)       240 (62.5)       844 (67.8)       0.008         Headache       598 (69.5)       256 (66.7)       854 (68.6)       0.328         Diarrhea       191 (22.2)       71 (18.5)       262 (21.0)       0.140         Cough/expectoration       747 (86.8)       321 (83.6)       1068 (85.8)       0.140         Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002			, ,	, ,	
Headache       598 (69.5)       256 (66.7)       854 (68.6)       0.328         Diarrhea       191 (22.2)       71 (18.5)       262 (21.0)       0.140         Cough/expectoration       747 (86.8)       321 (83.6)       1068 (85.8)       0.140         Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002	•	` ′		, ,	
Diarrhea       191 (22.2)       71 (18.5)       262 (21.0)       0.140         Cough/expectoration       747 (86.8)       321 (83.6)       1068 (85.8)       0.140         Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002	•	` ′		, ,	
Cough/expectoration       747 (86.8)       321 (83.6)       1068 (85.8)       0.140         Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002		, ,		, ,	
Stuffy/running nose       704 (81.8)       281 (73.2)       985 (79.1)       0.001         Dyspnea       158 (18.4)       43 (11.2)       201 (16.1)       0.002		, ,		, ,	
Dyspnea 158 (18.4) 43 (11.2) 201 (16.1) 0.002	<u> </u>	, ,	, ,	, ,	
		· · ·		, ,	
Fatigue 602 (69.9) 232 (60.4) 834 (67.0) 0.001	* *			, ,	
	Fatigue	602 (69.9)	232 (60.4)	834 (67.0)	0.001

COVID-19 vaccination

Yes $(n = 1208)$	828 (96.2)	380 (99.0)	1208 (97.0)	0.007
No $(n = 37)$	33 (3.8)	4 (1.0)	37 (3.0)	0.007

#Comorbidity or special condition includes hypertension, diabetes, cardiovascular disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial asthma, mental illness, and in the third trimester of pregnancy or perinatal period.

\*Multiple responses

412

Table 3 Association between taste disorder and demographic/COVID-19-related characteristics among patients

Variable	Taste disorder (%)		Total (%)	
Variable	Yes $(n = 843)$	No $(n = 402)$	Yes $(n = 1245)$	– p value
Sex				
Male	167 (19.8)	95 (23.6)	262 (21.0)	0.122
Female	676 (80.2)	307 (76.4)	983 (79.0)	0.122
Age, years				
18–29	687 (81.5)	342 (85.1)	1029 (82.7)	
30–39	113 (13.4)	41 (10.2)	154 (12.4)	0.430
40–49	32 (3.8)	14 (3.5)	46 (3.7)	0.430
≥ 50	11 (1.3)	5 (1.2)	16 (1.3)	
Smoking				
Current	27 (3.2)	10 (2.5)	37 (3.0)	0.104
Former	37 (4.4)	10 (2.5)	47 (3.8)	0.194
Never	779 (92.4)	382 (95.0)	1161 (93.3)	
Alcohol	•	. ,	,	
Yes	430 (51.0)	195 (48.5)	625 (50.2)	0.400
No	413 (49.0)	207 (51.5)	620 (49.8)	0.409
Chronic rhinitis	` ,	` '	, ,	
Yes	129 (15.3)	56 (13.9)	185 (14.9)	0.504
No	714 (84.7)	346 (86.1)	1060 (85.1)	0.524
Allergic rhinitis	· · · · /	` /	` '	
Yes	206 (24.4)	93 (23.1)	299 (24.0)	0 -1-
No	637 (75.6)	309 (76.9)	946 (76.0)	0.615
Any comorbidity or special	()	(1.2.2)	- ()	
ondition <sup>#</sup>				
Yes	109 (12.9)	39 (9.7)	148 (11.9)	0.400
No	734 (87.1)	363 (90.3)	1097 (88.1)	0.100
Method of diagnosis		· -/	` '	
PCR test	135 (16.0)	66 (16.4)	201 (16.1)	
Antigen test	438 (52.0)	221 (55.0)	659 (52.9)	0.466
Symptoms	270 (32.0)	115 (28.6)	385 (30.9)	
Rehabilitation status	· · · · · ·	-/	, ,	
Complete	292 (34.6)	158 (39.3)	450 (36.1)	0.400
Partial	551 (65.4)	244 (60.7)	795 (63.9)	0.109
Symptoms*	()	( · · )	(·-)	
Fever	800 (94.9)	376 (93.5)	1176 (94.5)	0.324
Lack of appetite	554 (65.7)	161 (40.0)	715 (57.4)	< 0.001
Dry and sore throat	677 (80.3)	299 (74.4)	976 (78.4)	0.017
Myalgia	591 (70.1)	253 (62.9)	844 (67.8)	0.017
Headache	599 (71.1)	255 (63.4)	854 (68.6)	0.007
Diarrhea	196 (23.3)	66 (16.4)	262 (21.0)	0.006
Cough/expectoration	739 (87.7)	329 (81.8)	1068 (85.8)	0.006
Stuffy/running nose	681 (80.8)	304 (75.6)	985 (79.1)	0.036
Dyspnea Dyspnea	158 (18.7)	43 (10.7)	201 (16.1)	< 0.001
Fatigue	598 (70.9)	236 (58.7)	834 (67.0)	< 0.00

# COVID-19 vaccination

Yes	814 (96.6)	394 (98.0)	1208 (97.0)	0.150			
No	29 (3.4)	8 (2.0)	37 (3.0)	0.159			
415	415 *Comorbidity or special conditions included hypertension, diabetes, cardiovascular						
416	6 disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic						
417	kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial						
418	asthma, mental illness, and in the third trimester of pregnancy or perinatal period.						
419	*Multiple responses.						
420							

# 421 Table 4 Association between chemesthesis disorder and patient demographic

422 characteristics

422 <b>characteristics</b> Chemesthesis disorder (%) Total (%)						
Variable	-	Chemesthesis disorder (%)		- p value		
	Yes $(n = 391)$	No $(n = 854)$	Yes $(n = 1245)$	F - 4140		
Sex						
Male	70 (17.9)	192 (22.5)	262 (21.0)	0.066		
Female	321 (82.1)	662 (77.5)	983 (79.0)	0.000		
Age, years						
18–29	310 (79.3)	719 (84.2)	1029 (82.7)			
30–39	60 (15.3)	94 (11.0)	154 (12.4)	0.160		
40–49	15 (3.8)	31 (3.6)	46 (3.7)	0.100		
≥ 50	6 (1.5)	10 (1.2)	16 (1.3)			
Smoking						
Current	12 (3.1)	25 (2.9)	37 (3.0)	0.914		
Former	16 (4.1)	31 (3.6)	47 (3.8)	0.714		
Never	363 (92.8)	798 (93.4)	1161 (93.3)			
Alcohol						
Yes	203 (51.9)	422 (49.4)	625 (50.2)	0.412		
No	188 (48.1)	432 (50.6)	620 (49.8)	0.412		
Chronic rhinitis						
Yes	62 (15.9)	123 (14.4)	185 (14.9)	0.503		
No	329 (84.1)	731 (85.6)	1060 (85.1)	0.505		
Allergic rhinitis						
Yes	86 (22.0)	213 (24.9)	299 (24.0)	0.259		
No	305 (78.0)	641 (75.1)	946 (76.0)	0.237		
Any comorbidity or special						
condition <sup>#</sup>						
Yes	49 (12.5)	99 (11.6)	148 (11.9)	0.635		
No	342 (87.5)	755 (88.4)	1097 (88.1)	0.033		
Method of diagnosis						
PCR test	60 (15.3)	141 (16.5)	201 (16.1)	0.693		
Antigen test	204 (52.2)	455 (53.3)	659 (52.9)	0.093		
Symptoms	127 (32.5)	258 (30.2)	385 (30.9)			
Rehabilitation status						
Complete	126 (32.2)	324 (37.9)	450 (36.1)	0.051		
Partial	265 (67.8)	530 (62.1)	795 (63.9)	0.031		
Symptoms*						
Fever	369 (94.4)	807 (94.5)	1176 (94.5)	0.930		
Lack of appetite	261 (66.8)	454 (53.2)	715 (57.4)	< 0.001		
Dry and sore throat	312 (79.8)	664 (77.8)	976 (78.4)	0.416		
Myalgia	270 (69.1)	574 (67.2)	844 (67.8)	0.519		
Headache	266 (68.0)	588 (68.9)	854 (68.6)	0.772		
Diarrhea	84 (21.5)	178 (20.8)	262 (21.0)	0.797		
Cough/expectoration	341 (87.2)	727 (85.1)	1068 (85.8)	0.329		
Stuffy/running nose	309 (79.0)	676 (79.2)	985 (79.1)	0.959		
Dyspnea	87 (22.3)	114 (13.3)	201 (16.1)	< 0.001		
Fatigue	284 (72.6)	550 (64.4)	834 (67.0)	0.004		
C	` -/		` /			

# COVID-19 vaccination

Yes	374	(95.7)	834 (97.7)	1208 (97.0)	0.053		
No	17 (4	1.3)	20 (2.3)	37 (3.0)	0.055		
423	423 *Comorbidity or special conditions included hypertension, diabetes, cardiovascular						
424	disease, cerebrovascular disease, neoplastic disease, immune deficiency, chronic						
425	kidney disease, thyroid disease, rheumatoid arthritis, spinal joint disease, bronchial						
426	asthma, mental illness, and in the third trimester of pregnancy or perinatal period.						
427	*Multiple response.						
428							